[1]李 苗,龚 姗,金海红,等.上皮性卵巢癌组织CDCA7 表达水平及其与患者预后的相关性研究[J].现代检验医学杂志,2023,38(02):118-123.[doi:10.3969/j.issn.1671-7414.2023.02.022 ]
　LI Miao,GONG Shan,JIN Hai-hong,et al.Expression Level of CDCA7 in Epithelial Ovarian Cancer Tissues and Its Correlation with Prognosis of Patients[J].Journal of Modern Laboratory Medicine,2023,38(02):118-123.[doi:10.3969/j.issn.1671-7414.2023.02.022 ]
点击复制

上皮性卵巢癌组织CDCA7 表达水平及其与患者预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年02期
页码:
118-123
栏目:
论著
出版日期:
2023-03-15

文章信息/Info

Title:
Expression Level of CDCA7 in Epithelial Ovarian Cancer Tissues and Its Correlation with Prognosis of Patients
文章编号:
1671-7414（2023）02-118-06
作者:
李 苗; 龚 姗; 金海红; 付静静; 韩 坤
（秦皇岛市第一医院妇科，河北秦皇岛 066000）
Author(s):
LI Miao; GONG Shan; JIN Hai-hong; FU Jing-jing; HAN Kun
（Department of Gynaecology, the first Hospital of Qinhuangdao City, Hebei Qinhuangdao 066000, China）
关键词:
上皮性卵巢癌; 细胞分裂周期相关蛋白 7
分类号:
R737.31；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.02.022
文献标志码:
A
摘要:
目的 探讨上皮性卵巢癌（epithelial ovarian cancer，EOC）组织细胞分裂周期相关蛋白（cell division cycle associated protein 7，CDCA7）表达水平及其与患者预后的相关性。方法 收集 2010年 10月～2020年 10月河北省秦皇岛市第一医院收治的 90例 EOC患者癌组织标本和 50例癌旁组织标本，采用免疫组织化学法检测癌组织、癌旁组织标本 CDCA7阳性表达情况；采用实时荧光定量（qRT-PCR）法检测癌组织、癌旁组织标本 CDCA7 mRNA相对表达量。比较 EOC癌组织标本中 CDCA7表达情况与临床病理特征的关系； Kaplan-Meier法分析 EOC癌组织标本中 CDCA7表达情况与患者无进展生存期（progression-free survival，PFS）和生存率的相关性以及 COX风险比例回归分析影响预后的因素。结果 CDCA7蛋白在 EOC癌组织中阳性表达率为 78.33%，高于癌旁组织的 64.17%，差异有统计学意义（χ2=70.767，P=0.000）；CDCA7mRNA在癌组织中的相对表达量为 6.05±0.32，高于癌旁组织（1.08±0.06），差异有统计学意义（t=108.600, P=0.000）；CDCA7高表达与 EOC患者病理分期、肿瘤浸润深度、病理分型、淋巴结转移、CA125水平和 HE4水平等临床特征有关（χ2= 3.947～8.420，均 P＜ 0.05）；Kaplan-Meier法生存分析， CDCA7低表达 EOC患者 PFS生存时间为 98.15±10.72个月，高于 CDCA7高表达患者（63.25±7.49个月），差异有统计学意义（Log-Rank χ2=3.849，P=0.049）；CDCA7低表达患者 12个月的总生存率为 87.35%，高于 CDCA7高表达患者的 45.76%，差异有统计学意义（Log-Rank χ2=6.905，P=0.012）；COX比例风险回归， TNM分期为Ⅲ～Ⅳ期、并发淋巴结转移、CDCA7高表达为影响患者 12个月 PFS的独立危险因素（Wald χ2=4.858, 4.892, 5.025，P=0.028，0.028，0.026）。结论 CDCA7在 EOC患者癌组织中阳性表达率高于癌旁组织，CDCA7高表达是影响患者 12个月 PFS的独立危险因素，可作为 EOC患者不良预后评估的分子标志物。
Abstract:
Objective To explore the expression level of cell division cycle associated protein 7 (CDCA7) in epithelial ovarian cancer (EOC) tissues and its correlation with prognosis of patients. Methods The cancer tissue samples from 90 EOC patients and para-cancerous tissue samples from 50 EOC patients admitted to the first Hospital of Qinhuangdao City were collected between October 2010 and October 2020. The positive expression of CDCA7 in cancer tissues and para-cancerous tissues was detected by immunohistochemistry. The relative expression level of CDCA7 mRNA in cancer tissues and para-cancerous tissues was detected by real-time fluorescence quantitative PCR (qRT-PCR). The relationship between CDCA7 in EOC tissues and clinicopathological characteristics was compared. The correlation between CDCA7 in EOC tissues and progression-free survival (PFS), survival rate was analyzed by Kaplan-Meier. The influencing factors of prognosis were analyzed by COX hazard proportional regression model. Results The positive expression rate of CDCA7 protein in EOC tissues was higher than that in para-cancerous tissues (78.33% vs 64.17%) ，the difference was statistically significant (χ2=70.767，P=0.000). The relative expression level of CDCA7 mRNA in cancer tissues was higher than that in para-cancerous tissues (6.05±0.32 vs 1.08±0.06), the difference was statistically significant (t=108.600, P=0.000). The high-expression CDCA7 was correlated with pathological staging, tumor invasion depth, pathological classifications, lymph node metastasis, CA125 and HE4 levels (χ2= 3.947～8.420，all P＜ 0.05). Kaplan-Meier survival analysis showed that PFS in EOC patients with low-expression CDCA7 was longer than that with high-expression CDCA7 (98.15±10.72 months vs 63.25±7.49 months), the difference was statistically significant（Log-Rank χ2=3.849，P=0.049）and 12-month overall survival rate was higher than that with high-expression CDCA7(87.35% vs 45.76%) and the difference was statistically significant(Log-Rank χ2=6.905，P=0.012). COX hazard proportional regression model showed that TNM staging at stage III-IV, lymph node metastasis and high-expression CDCA7 were independent risk factors of 12-month PFS (Wald χ2=4.858, 4.892, 5.025, P=0.028，0.028，0.026). Conclusion The positive expression rate of CDCA7 in cancer tissues was higher than that in para-cancerous tissues in EOC patients. The high-expression CDCA7 is an independent risk factor of 12-month PFS, which can be applied as a molecular marker to evaluate poor prognosis of EOC patients.

参考文献/References:

[1] LHEUREUX S, GOURLEY C, VERGOTE I, et al. Epithelial ovarian cancer[J]. Lancet, 2019, 393(10177): 1240-1253.
[2] KURNIT K C, flEMING G F, LENGYEL E. Updates and new options in advanced epithelial ovarian cancer treatment[J]. Obstetrics and Gynecology, 2021, 137(1): 108-121.
[3] 付妮娜 , 范婧晖 , 钟慧． CA125,HE4和 MMP7联合检测在Ⅰ型和Ⅱ型上皮性卵巢癌患者诊断中的价值 [J]．现代检验医学杂志 , 2019, 34(6): 109-112, 156． FU Nina, FAN Jinghui, ZHONG Hui. Diagnostic value of combined detection of CA125, HE4 and MMP7 in type Ⅰ and Ⅱ epithelial ovarian cancer[J]. Journal of Modern Laboratory Medicine, 2019, 34(6): 109-112, 156.
[4] SAVA G P, FAN Hailing, COOMBES R C, et al. CDK7 inhibitors as anticancer drugs[J]. Cancer Metastasis Reviews, 2020, 39(3): 805-823.
[5] CAI Chunyan, PENG Xing, ZHANG Yumei. Downregulation of cell division cycle-associated protein 7 (CDCA7) suppresses cell proliferation, arrests cell cycle of ovarian cancer, and restrains angiogenesis by modulating enhancer of zeste homolog 2 (EZH2) expression[J]. Bioengineered, 2021, 12(1): 7007-7019.
[6] 邓路 , 何志伟 , 朱昌毫 , 等．CDCA7通过与 MCM3相互作用介导胰腺癌细胞增殖、侵袭及迁移 [J].肿瘤 , 2021, 41(1): 24-35． DENG Lu, HE Zhiwei, ZHU Changhao, et al. CDCA7 mediates proliferation, invasion and migration of pancreatic cancer cells by interacting with MCM3[J]. Tumor, 2021, 41(1): 24-35.
[7] 胡德献 , 孙衍昶 , 冯基高 , 等．CDCA7L在人脑胶质瘤组织中的表达及意义 [J]．中国临床神经外科杂志 , 2020, 25(12): 834-837． HU Dexian, SUN Yanchang, FENG Jigao, et al. Expression of CDCA7L in human glioma tissues and its clinical significance[J]. Chinese Journal of Clinical Neurosurgery, 2020, 25(12): 834-837.
[8] 连利娟．林巧稚妇科肿瘤学 [M]．4版．北京 : 人民卫生出版社 , 2006． LIAN Lijuan. Lin Qiaozhi’s Gynecological Oncology[M].4th Ed .Beijing: People’s Medical Publishing House, 2006.
[9] 李晶 , 吴妙芳 , 林仲秋．《 2012NCCN卵巢癌包括输卵管癌和原发腹膜癌临床实践指南 (第二版 )》解读 (续 )-上皮性卵巢癌 [J].国际妇产科学杂志 , 2012, 39(3): 315-318． LI Jing, WU Miaofang, LIN Zhongqiu. 2012 NCCN clinical practice guide for ovarian cancer including fallopian tube cancer and primary peritoneal cancer(Second Edition)-Epithelial Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2012, 39(3): 315-318.
[10] VERMORKEN J B, VAN DAM P, BRAND A. HIPEC in advanced epithelial ovarian cancer: why is there controversy?[J]. Current Opinion in Oncology, 2020, 32(5): 451-458.
[11] 周潇妮 ,付振华 , 张琦玲 , 等 . 基于整合组学探讨细胞周期相关基因在高级别浆液性卵巢癌发生及发展中的作用 [D].南昌 : 南昌大学学报 (医学版 ), 2020, 60(3): 19-25. ZHOU Xiaoni, FU Zhenhua, ZHANG Qiling, et al. Investigation of role of cell cycle-related genes in occurrence and development of high-grade serous ovarian cancer based on integrated omics[J]. Journal of Nanchang University(Medical Sciences), 2020, 60(3):19-25.
[12] MAHDESSIAN D, CESNIK A J, GNANN C, et al. Spatiotemporal dissection of the cell cycle with single-cell proteogenomics[J]. Nature, 2021, 590(7847): 649-654.
[13] 王莉洁 , 韩曦 , 郑霞 , 等．人参皂苷 20(S)-Rg3通过抑制 DNMT3A介导的启动子甲基化促进卵巢癌细胞中抑癌基因 VHL的表达 [J]．南方医科大学学报 , 2021, 41(1): 100-106． WANG Lijie, HAN Xi, ZHENG Xia, et al. Ginsenoside 20(S)-Rg3 upregulates tumor suppressor VHL gene expression by suppressing DNMT3A-mediated promoter methylation in ovarian cancer cells[J]. Journal of Southern Medical University, 2021, 41(1): 100-106.
[14] 马欢 , 田小飞 , 李红霞．复发性卵巢癌患者血清 NDRG4水平表达与临床特征及预后的相关性研究 [J]．现代检验医学杂志 , 2019, 34(5): 81-83． MA Huan, TIAN Xiaofei, LI Hongxia. Correlation between serum NDRG4 expression and clinical features and prognosis in patients with recurrent ovarian cancer[J]. Journal of Modern Laboratory Medicine, 2019, 34(5): 81-83.
[15] JIMéNEZ-P R, MARTíN-CORTáZAR C, KOURANI O, et al. CDCA7 is a critical mediator of lymphomagenesis that selectively regulates anchorage-independent growth[J]. Haematologica, 2018, 103(10): 1669-1678.
[16] 杨得草 , 刘程 , 马集 , 等．细胞分裂周期相关蛋白 7通过增强细胞增殖和干性促进入乳腺癌进程 [J]．解剖学报 , 2020, 51(6): 888-896． YANG Decao, LIU Cheng, MA Ji, et al. Cell division cycle associated 7 promoteing breast cancer progression by enhancing proliferation and stemness of breast cancer cell [J]. Acta Anatomica Sinica, 2020, 51(6): 888-896.
[17] ROSKOSKI R. Cyclin-dependent protein serine/ threonine kinase inhibitors as anticancer drugs[J]. Pharmacol Res, 2019,139:471-488.
[18] YE Liping, LI Fengyan, SONG Yipeng, et al. Over expression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer[J]. International Journal of Cancer, 2018, 143(10): 2602-2613.
[19] LI Siman, HUANG Jiean, QIN Mengbin, et al. High expression of CDCA7 predicts tumor progression and poor prognosis in human colorectal cancer[J]. Molecular Medicine Reports, 2020, 22(1): 57-66.
[20] 常旺燕 , 李爱明 , 窦丽 , 等．TRIM21通过 Wnt/ β-catenin信号通路调控卵巢癌细胞增殖及耐药 [J].中国肿瘤生物治疗杂志 , 2020, 27(7): 749-756. CHANG Wangyan, LI Aiming, DOU Li, et al. TRIM21 regulates proliferation and drug resistance of ovarian cancer cells through Wnt/β-catenin signaling pathway [J]. Chinese Journal of Cancer Biotherapy, 2020, 27(7): 749-756.

相似文献/References:

[1]林燕玲,王　瑛,张　敏,等.上皮性卵巢癌组织中miR-506-3p及miR-532-5p的表达与临床病理特征及预后的相关研究[J].现代检验医学杂志,2022,37(03):83.[doi:10.3969/j.issn.1671-7414.2022.03.017]
　LIN Yan-ling,WANG Ying,ZHANG Min,et al.Correlation between the Expression of miR-506-3p and miR-532-5p and Clinicopathological Features and Prognosis in Epithelial Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2022,37(02):83.[doi:10.3969/j.issn.1671-7414.2022.03.017]
[2]邓森灵,兰代群,曹雅文,等.上皮性卵巢癌患者血清miR-362 和miR-485 的表达水平及其与预后的相关性研究[J].现代检验医学杂志,2022,37(04):35.[doi:10.3969/j.issn.1671-7414.2022.04.007]
　DENG Sen-ling,LAN Dai-qun,CAO Ya-wen,et al.Expression of miR-362 and miR -485 in Serum of Patients with Epithelial Ovarian Cancer and Their Correlation with Prognosis[J].Journal of Modern Laboratory Medicine,2022,37(02):35.[doi:10.3969/j.issn.1671-7414.2022.04.007]

备注/Memo

备注/Memo:
收稿日期：2022-04-21修回日期：2022-08-24
基金项目：河北省医学科学研究课题计划项目（20221606）；秦皇岛市科学技术研究与发展项目（202101A066）。
作者简介：李苗（1979-），女，本科，副主任护师，研究方向：妇科肿瘤， E-mail：lkdd20220415@163.com。
通讯作者：龚姗（1986-），女，副主任医师， E-mail：lunazi2233@163.com。

更新日期/Last Update: 2023-03-15